Targeting the epigenome for the treatment and prevention of lung cancer

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Aberrant DNA methylation and histone modifications are key drivers of gene expression changes in pulmonary carcinogenesis.
• Epigenetic alterations in chromatin structure play a significant role in the development of lung cancer.

Purpose of the Study:

• To investigate the synergistic effects of DNA demethylating agents and histone deacetylase (HDAC) inhibitors on lung cancer cells.
• To evaluate the potential of chromatin remodeling agents for the treatment and prevention of lung cancer.

Main Methods:

• Utilizing cultured lung cancer cells to assess the impact of demethylating agents and HDAC inhibitors on gene expression and apoptosis.
• Conducting animal studies following exposure to tobacco carcinogens to evaluate cancer prevention efficacy.
• Analyzing preliminary clinical trial data on the use of these agents in lung cancer patients.

Main Results:

• DNA demethylating agents and HDAC inhibitors synergistically induce gene expression and apoptosis in lung cancer cells.
• These agents demonstrated efficacy in preventing lung cancer development in animal models.
• Preliminary clinical trials confirmed proof of principle for enhancing cancer cell immunogenicity and apoptosis, while highlighting mechanistic complexities.

Conclusions:

• Epigenetic dysregulation is central to lung cancer development.
• Chromatin remodeling agents, including DNA demethylating agents and HDAC inhibitors, represent a promising therapeutic and preventive strategy for lung cancer.
• Further research into the mechanisms of chromatin remodeling agents is warranted for optimizing lung cancer treatment and prevention.